Hangzhou Tigermed Consulting Co., Ltd (SHE:300347)
China · Delayed Price · Currency is CNY 51.40
-1.39 (-2.63%)
Sep 1, 2026, 3:04 PM CST
SHE:300347 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 41,884 | 46,212 | 43,882 | 44,807 | 87,567 | 104,196 | |
Market Cap Growth | -19.03% | 5.31% | -2.06% | -48.83% | -15.96% | -25.42% |
Enterprise Value | 45,702 | 49,783 | 49,344 | 44,345 | 85,466 | 98,831 |
Last Close Price | 52.79 | 56.54 | 54.15 | 53.86 | 101.80 | 123.39 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 458.28 | 52.05 | 108.31 | 22.13 | 43.64 | 36.25 |
Forward PE | 43.02 | 48.80 | 28.29 | 19.90 | 32.89 | 48.60 |
PS Ratio | 5.75 | 6.76 | 6.65 | 6.07 | 12.36 | 19.99 |
PB Ratio | 1.81 | 1.91 | 1.82 | 1.83 | 3.86 | 5.06 |
P/TBV Ratio | 2.65 | 2.69 | 2.57 | 2.50 | 5.23 | 6.47 |
P/FCF Ratio | 45.74 | 51.14 | 59.27 | 53.55 | 96.34 | 98.75 |
P/OCF Ratio | 36.89 | 41.33 | 40.00 | 38.95 | 64.51 | 73.18 |
PEG Ratio | - | 5.01 | 3.69 | 1.20 | 1.89 | 3.81 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 6.27 | 7.29 | 7.47 | 6.01 | 12.06 | 18.96 |
EV/EBITDA Ratio | 47.13 | 60.69 | 40.62 | 23.64 | 44.48 | 67.77 |
EV/EBIT Ratio | 70.62 | 81.82 | 48.88 | 26.23 | 48.48 | 73.55 |
EV/FCF Ratio | 49.91 | 55.09 | 66.64 | 53.00 | 94.03 | 93.66 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.10 | 0.07 | 0.12 | 0.14 | 0.12 | 0.05 |
Debt / EBITDA Ratio | 2.42 | 1.79 | 2.12 | 1.68 | 1.34 | 0.64 |
Debt / FCF Ratio | 2.56 | 1.86 | 3.83 | 4.00 | 2.99 | 0.92 |
Net Debt / Equity Ratio | 0.01 | -0.01 | 0.03 | -0.17 | -0.23 | -0.37 |
Net Debt / EBITDA Ratio | 0.24 | -0.20 | 0.57 | -2.22 | -2.69 | -5.21 |
Net Debt / FCF Ratio | 0.22 | -0.18 | 0.93 | -4.97 | -5.68 | -7.20 |
Asset Turnover | 0.26 | 0.24 | 0.23 | 0.26 | 0.28 | 0.24 |
Inventory Turnover | 98.38 | 135.03 | 157.49 | 199.06 | 302.27 | 544.16 |
Quick Ratio | 2.38 | 2.11 | 1.68 | 2.72 | 2.95 | 4.46 |
Current Ratio | 2.49 | 2.18 | 1.72 | 2.74 | 2.98 | 4.50 |
Return on Equity (ROE) | 1.09% | 3.33% | 1.85% | 9.12% | 10.50% | 17.64% |
Return on Assets (ROA) | 1.43% | 1.33% | 2.16% | 3.70% | 4.30% | 3.88% |
Return on Invested Capital (ROIC) | 1.46% | 2.00% | 3.02% | 7.72% | 10.15% | 11.76% |
Return on Capital Employed (ROCE) | 2.60% | 2.40% | 4.00% | 6.60% | 7.40% | 6.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 0.22% | 1.92% | 0.92% | 4.52% | 2.29% | 2.76% |
FCF Yield | 2.19% | 1.96% | 1.69% | 1.87% | 1.04% | 1.01% |
Dividend Yield | 0.23% | 0.22% | 0.55% | 1.05% | 0.54% | 0.40% |
Payout Ratio | 121.79% | 38.70% | 158.50% | 29.13% | 24.52% | 9.89% |
Buyback Yield / Dilution | -0.43% | 0.83% | 0.22% | 0.07% | 0.62% | -9.01% |
Total Shareholder Return | -0.19% | 1.05% | 0.78% | 1.12% | 1.16% | -8.60% |